Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Clinical trial NCT05184335 · RECRUITING
Trial details
- NCT number
- NCT05184335
- Sponsor
- Reviva Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-24
- Primary completion
- 2025-02-01
- Enrollment
- 690
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.